Tobira closes $31mm Series B round
Executive Summary
Antiviral therapeutics developer Tobira Therapeutics Inc. raised $14.2mm in its Series B financing led by new backer Novo AS with additional participation from Series A investors Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners, and Canaan Partners, as well as one undisclosed investor. The company plans to raise another $17mm in the round. The funds will support the Phase IIb trial for its lead compound TBR652 for HIV.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice